NovoNeuron

NovoNeuron is an Australian biotechnology company focused on developing neuroprotective therapies for acute and chronic neurological conditions. The company's lead research centers on a novel class of small molecule inhibitors designed to target the N-methyl-D-aspartate (NMDA) receptor to prevent excitotoxicity without the side effects typically associated with traditional NMDA antagonists. Their primary focus is on treating traumatic brain injury (TBI) and stroke, where rapid neuroprotection is critical to improving patient outcomes. By leveraging intellectual property originating from the University of Queensland, NovoNeuron aims to bridge the gap between academic discovery and clinical application in the field of neuroscience.